Monument Healthcare: Failed Drug Reduction Reviews - UT
Resident 20, who has schizoaffective disorder and depression, has been on clozapine since March 2023 without receiving a gradual dose reduction review, according to a September federal inspection. The facility's Director of Nursing admitted he could not find evidence that any reduction had been attempted.
Federal regulations require nursing homes to try gradually reducing psychotropic medications unless clinically contraindicated, as part of efforts to eventually discontinue these drugs when possible. The facility failed to document any clinical reason why dose reductions shouldn't be attempted for this resident.
When inspectors observed the resident on September 2, they found him sleeping in bed during three separate checks at 9:16 AM, 10:02 AM, and 12:17 PM. The resident was taking 100 mg of clozapine daily, prescribed on March 14, 2023, with an additional 150 mg dose also ordered the same day for his schizoaffective disorder.
Clozapine is typically reserved for treatment-resistant schizophrenia and carries significant risks, including potentially fatal blood disorders. The medication requires regular blood monitoring and careful dosage management.
The Director of Nursing told inspectors that psychotropic medication meetings occur on the third Wednesday of every month, where residents' medications are reviewed at least quarterly. When residents begin a gradual dose reduction, they are supposed to be reviewed at the following month's meeting.
But for Resident 20, no such process had begun.
"The DON stated that resident 20 had been on clozapine since March of 2023 and he could not find if a GDR had been done," the inspection report states, using the abbreviation for gradual dose reduction.
The failure represents a breakdown in the facility's medication oversight system. While the nursing home claims to hold monthly psychotropic meetings and quarterly reviews, these processes apparently failed to identify that Resident 20 had been on the same antipsychotic regimen for nearly two years without any attempt at reduction.
Federal guidelines emphasize that psychotropic medications should be used only when necessary and at the lowest effective dose. The goal is to minimize residents' exposure to these powerful drugs, which can cause sedation, movement disorders, and other serious side effects, particularly in elderly populations.
The inspection found that Monument Healthcare failed this standard for one out of 19 residents whose records were sampled, suggesting the problem may be more widespread than documented.
Psychotropic medications like clozapine can significantly impact a resident's ability to function independently. The drugs may cause excessive sedation, confusion, and mobility problems that can increase fall risks and reduce quality of life. Regular dose reduction attempts help ensure residents aren't taking higher doses than medically necessary.
The facility's own policies require monthly meetings specifically dedicated to reviewing these medications, yet the system failed to catch that Resident 20's doses had remained static since his admission. The Director of Nursing's inability to locate any gradual dose reduction documentation suggests either the reviews weren't happening as claimed or weren't being properly recorded.
Monument Healthcare's violation was classified as causing minimal harm or potential for actual harm, affecting few residents. However, the failure to attempt dose reductions over nearly two years raises questions about the facility's commitment to minimizing residents' exposure to powerful psychiatric medications.
The inspection occurred following a complaint, though the report doesn't specify the nature of the complaint that triggered the federal review. Inspectors completed their work on September 4, 2025.
For Resident 20, the prolonged period without dose reduction attempts means nearly two years of potentially unnecessary exposure to clozapine's risks. The medication's side effects can include severe drowsiness, which may explain why inspectors found the resident sleeping during multiple daytime observations.
The facility now faces federal oversight to correct its psychotropic medication review processes. But for residents like Resident 20, the damage of extended exposure to powerful psychiatric drugs without proper oversight has already occurred.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Monument Healthcare American Fork from 2025-09-04 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Monument Healthcare American Fork in American Fork, UT was cited for violations during a health inspection on September 4, 2025.
The facility's Director of Nursing admitted he could not find evidence that any reduction had been attempted.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.